Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

This study is testing a combination of cetuximab (an anti-EGFR antibody), envafolimab (a PD-L1 checkpoint inhibitor), and a chemotherapy regimen called mFOLFOXIRI as a first-line treatment for people with RAS/BRAF wild-type, left-sided, microsatellite stable metastatic colorectal cancer. **You may be eligible if...** - You are 18 or older with confirmed metastatic colorectal cancer that has specific genetic features (RAS/BRAF wild-type, MSS) and is located on the left side of the colon - You have not previously received any systemic treatment for your metastatic cancer - Your overall health is good (ECOG 0–1) and organ function is adequate **You may NOT be eligible if...** - You have had recent blood clots, a heart attack, or serious heart condition in the past 12 months - You have active autoimmune disease, HIV, or active hepatitis B or C - You are currently taking antibiotics for more than a week for an infection - You have uncontrolled fluid buildup around your lungs or abdomen - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.